TNF-α-related apoptosis inducing ligand (TRAIL) therapy is often limited by the drug-resistance of cancer cells, although TRAIL is an attractive anticancer agent owing to its selective targeting of cancer cells. This evidence concerns the gene TNFSF10 and cancer.